Please login to the form below

Not currently logged in
Email:
Password:

pegpleranib

This page shows the latest pegpleranib news and features for those working in and with pharma, biotech and healthcare.

Novartis buys two firms in pre-Christmas shopping spree

Novartis buys two firms in pre-Christmas shopping spree

Those only gathered pace after a late-stage setback for age-related macular degeneration (AMD) therapy Fovista (pegpleranib), which was licensed by the company in 2014 in a deal valued at

Latest news

  • Novartis' AMD drug pegpleranib fails phase III programme Novartis' AMD drug pegpleranib fails phase III programme

    Novartis' hopes of positioning pegpleranib as a duo alongside its big-selling age-related macular degeneration (AMD) drug Lucentis have been dashed. ... The key message from the data is that the proven efficacy of Lucentis monotherapy was not improved by

  • Novartis says Cosentyx is 'outpacing competitors' Novartis says Cosentyx is 'outpacing competitors'

    These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics